Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline
"This financing positions us to accelerate our efforts to advance our lead program VO659, currently in a Phase 1/2a clinical study of patients with spinocerebellar ataxia types 3 and 1 and Huntington's disease," said Micah Mackison, chief executive officer at Vico.
- "This financing positions us to accelerate our efforts to advance our lead program VO659, currently in a Phase 1/2a clinical study of patients with spinocerebellar ataxia types 3 and 1 and Huntington's disease," said Micah Mackison, chief executive officer at Vico.
- The financing will also help support discovery and research efforts to further expand the company's pipeline in other genetic neurological diseases.
- The company also announced that Jeroen Vangindertael, Ph.D., investment manager at AvH, will join Vico's board of directors.
- "We are proud to support Vico in this financing round as they continue to advance their lead clinical program and further develop a portfolio of novel antisense oligonucleotides," said Dr. Vangindertael.